Our study revealed that ertugliflozin treatment causes a decrease in HbA1c, AST, BS, ALT, TG, γ-GTP, uric acid, body weight, ferritin, and the FIB-4 ratio among NAFLD patients after 24 weeks. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.